FXYD5 and colorectal carcinoma: To gain further insight into the role of dysadherin in colorectal cancer (CRC) patients, we compared the gene expression profiles of tumors by dividing 62 CRC patient samples (GSE35896) and 104 CRC patient samples (GSE21510) into high dysadherin expression (Dyshigh) groups and low dysadherin expression (Dyslow) groups based on median values.